Published in AIDS Weekly, October 16th, 2000
D. Liu and colleagues from Enzo Therapeutics, Inc., New York, and the University of California tried "to restore immunocompetency in HIV-1 infected individuals by establishing a sustained population of peripheral blood mononuclear cells (PBMC) expressing anti-HIV-1 antisense RNA and resistant to HIV-1 infection."
D. Engelhardt, Enzo Therapeutics, presented data from the study at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 17-20,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2000-10-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.